Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 153Carcinoma, Non-Small-Cell Lung 94Neoplasms 57Breast Neoplasms 50Urinary Bladder Neoplasms 47Neoplasm Metastasis 43Lung Neoplasms 41Ovarian Neoplasms 36Cholangiocarcinoma 31Lymphoma 20Sarcoma 19Gallbladder Neoplasms 19Fallopian Tube Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Biliary Tract Neoplasms 18Recurrence 15Lymphoma, Non-Hodgkin 15Adenocarcinoma 14Hodgkin Disease 13Carcinoma, Transitional Cell 13Bile Duct Neoplasms 13Carcinoma 12Colorectal Neoplasms 10Head and Neck Neoplasms 8Carcinoma, Renal Cell 8Urethral Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Carcinoma, Ovarian Epithelial 7Adenocarcinoma of Lung 7Uterine Cervical Neoplasms 6

Interventions

bintrafusp alfa protein, human 2Radiotherapy 2Cisplatin 2fresolimumab 1enzalutamide 1Sorafenib 1Paclitaxel 1LY-2157299 1Gemcitabine 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Camurati-Engelmann Syndrome × Gemcitabine × Clear all
NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

EMD Serono

Phase 2/3 Terminated
309 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡